Strengthening Patient Access in Oncology Through Advocacy

BeOne Medicines has made building strong partnerships with patient organizations a deliberate, long-term practice, one that is integral to the patient-first approach that defines BeOne.

At the 2026 American Society of Clinical Oncology (ASCO) annual meeting, BeOne’s North America Patient Advocacy team brought together U.S. advocacy leaders, partners, and cross-functional colleagues around a shared goal: improving how patients access care today and in the future. We also shared the data BeOne featured at ASCO, grounding these conversations in science and evidence advancing our work.

Across more than a dozen engagements with over 25 advocacy leaders, one message came through clearly: BeOne’s approach is resonating. By listening first, acting with intention, and building long-term relationships, we are earning trust in ways that advance patient outcomes and strengthen our reputation as an oncology leader.

“We build transformational partnerships — rooted in listening and aligned to our business — that are focused on improving patient access and closing critical gaps in care,” said Lisa Porat, Director of Patient Partnership for North America. “Understanding what is and isn’t working enables us to take meaningful action with partners to address unmet patient need.”

During the meetings, advocacy partners spoke candidly about step edits, delays in care, NCCN guideline alignment, and the growing momentum for reform. They are interested in partnering on BeOne initiatives like the national CLL Report to use data and insights not only to understand gaps in care, but find solutions to help close them. We heard from state-based groups and Native American communities around how BeOne can expand partnerships, listen more deeply to localized access challenges, and support community-driven approaches to improve patient access across the U.S.

These realities shape patient journeys — and highlight where BeOne can be a constructive partner in driving progress.

Back in December at the 2025 American Society of Hematology (ASH) Annual Meeting, BeOne took the lead on an issue at the top of advocates’ minds — the use of artificial intelligence (AI) in delivering patient care. BeOne brought together patients, advocacy leaders, and AI experts to discuss how patients are using and feeling about this technology.

At ASCO six months later, advocacy leaders underscored the need for better tools to help patients navigate complex information and treatment decisions. They are excited about BeOne’s leadership in AI and, in particular, how we’ve applied emerging insights on AI-driven searches to optimize CLL Navigator™ — a digital resource and community for people with CLL (chronic lymphocytic leukemia) launched in May 2026. This tool was developed in collaboration with the CLL community and is designed for continuous evolution — mirroring how people seek information today: in an ongoing, personalized way beyond traditional clinical settings. These types of conversations are shaping new ideas for how BeOne can partner with the advocacy community to rethink the way patients access and use information.

Why is this important? According to a January report from OpenAI, more than 40 million regular ChatGPT users globally ask healthcare-related questions every day. About 70% of healthcare queries in the US take place after hours.¹

“Advocates are asking: How do we know what’s current? How do we know if the information is accurate?” she said. “They’re concerned about what resources and direction to provide to their communities and how to position themselves and their resources.”

Both CLL Navigator™ and the emerging efforts to address AI are part of BeOne’s commitment to patient care that extends beyond the clinic, into digital spaces.

For Porat, BeOne’s patient-first value is something BeOne demonstrates in practice with its advocacy partners, one conversation and one initiative at a time.

“Our relationships with advocacy partners are the heart of our core value. They validate our work every day. We say we put patients first, and our work with our advocacy partners demonstrates that we live it,” she says.